ALX raises $105M for midphase trials of CD47 cancer drug

ALX raises $105M for midphase trials of CD47 cancer drug

Submitted by admin on February 12, 2020 - 10:31am
Source: 
Fierce Biotech
News Tags: 
ALX Oncology
ALX148
cancewr
Headline: 
ALX raises $105M for midphase trials of CD47 cancer drug
snippet: 

ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies.

Do Not Allow Advertisers to Use My Personal information